Using this chronic kidney disease (CKD) precision medicine framework may improve participation in genetic testing to personalize health interventions.
Researchers from the University of Zurich found that a genetic variation present in about 30% of the population can affect how effective peritoneal dialysis is for these patients. Hospital leaders should be aware of this new precision medicine-based discovery.
University of Michigan Health System researchers and others are working for a fundamental change in kidney disease health economics and outcomes.
With a new Kidney Care Choices model starting January 1, 2022, hospital executives may be considering strategies, including precision medicine strategies.
Because of the increased number of risk adjustment programs, improved diagnosis and treatment of chronic kidney disease (CKD) could trigger substantial financial benefit. This research maps a path for physicians and health systems to better utilize existing medications for their patients with CKD.
